In our study, we found cardiocytes expressed CXCR4, and the number of cardiocytes apoptosis with SDF-1 treatment decreased obviously through SDF-1 induced the up-regulation of phosphorylated Akt. On day 7 after myocardial infarction, marked expression of SDF-1a, and the number of CD133 cells was the highest in the AdV-SDF-1 injection hearts. On day 28 post-treatment, blood vessel density in the AdV. q SDF-1 group was higher in infracted zones. Infarct size and collagen accumulation in the infracted area decreased significantly, thickness of LV wall, vessels and cardiocytes' density increased obviously in the AdV-SDF-1 group than in control or Adv-LacZ group, and hemodynamics showed the improvement of left ventricle heart function in the AdV.SDF-1 group. Therefore, SDF-1a could improve cardiac structure and function through the combined effects of angiogenesis and anti-apoptosis.
Introduction
Bone marrow (BM)-derived stem cells have been shown to home into the periinfarct region of the heart. This observation prompted a search for chemotactic factors that facilitate this 'homing' process w1x. Experimental myocardial infarction (MI) in mice increased the expression of stromal derived factor-1 alpha (SDF-1a) in the infarct and border region w2x. This provides the required stimulus for mobilization of stem cells from BM niches to the damaged site as a part of a natural repair process w3, 4x. SDF-1a specifically interacts with its receptor CXCR4 and orchestrates the mobilization and homing of stem cells from bone marrow (BM) to the ischemic tissue w1x. However, the effect of intrinsic SDF-1a upregulated expression is transient and insufficient for cardiac repair w3, 4x. Therefore, forced expression of SDF-1 by adenoviral gene delivery and SDF-1a protein increased the recruitment of BM-derived stem cells to the infarcted heart. Furthermore, SDF-1a protein and gene delivery to the ischemic heart promotes endothelial progenitor cells (EPCs, one of characteristic surface markers of EPCs is CD133) recruitment into the ischemic muscles to promote angiogenesis w4-6x. These findings raise the possibility that SDF-1a have the effects ૾ This study was supported by grants from National Natural Science Foundation of China (30700306).
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on myocardial structure and function via angiogenesis of stem cells homing. However, little information is available about the role of SDF-1 on angiogenesis and anti-apoptosis after MI.
The purpose of this study was to investigate whether SDF-1a directly decreases the cardiocytes apoptosis and, indirectly, induces CD133 EPCs migration into the injured q heart, and thereby changes myocardial histomorphology and improves cardiac function in a rat model of MI.
Methods
Methods in detail are available as a supplement from the author.
Results

Effect of hSDF-1a on myocardial conservation
CXCR4 expression in the cultured cadiocytes (Fig. 1a-c ) and normal heart (Fig. 1d) is demonstrated (Fig. 1a) . Cardiac myocytes in the infarct zone (Fig. 1e) and infarct border zone (Fig. 1f) 72 h after MI expressed CXCR4 and the level of cardiac myocyte CXCR4 expression within the infarct border zone increased greater than in infarct zone and normal heart. SDF-1 within the infarct zone led to a significant decrease in the number of TUNEL-positive cardiac myocyte nuclei (53% decreases) ( Fig. 1g-h ). The heart that overexpressed SDF-1 had greater phosphorylated Akt than control heart (Fig. 1i ). This decrease in cardiac (g-h). Merged image from an animal 72 h after LAD ligation in control group (g) and SDF-1 group (h) with cardiac Troponin T (red), TUNEL (green) and their nucleus stained with DAPI (blue) (400=). (i) Western-blotting of rat heart protein extract showed that besides elevated hSDF-1a expression. myocyte apoptosis was accompanied by a significant increase in the area of surviving bundles of cardiac myocytes within the infarct zone compared with control group (Fig. 3) .
Effect of hSDF-1a on CD133 stem cells homing
q into myocardium CD133 mRNA expression levels increased obviously in the infarcted area of the AdV.SDF-1 group compared with control group or AdV.LacZ group. Simultaneously, the number of cells expressing CD133 surface markers was significantly higher in the infarct areas of heart in the AdV.SDF-1 group, as compared with the other groups (Fig. 2) .
Effect of hSDF-1a on surviving cardiocytes and angiogenesis in the heart
The data in Fig. 3 demonstrate that SDF-1a, to a greater extent, increase the area and number of cardiac myocytes within the infarct zone (Fig. 3) . The angiogenic effect of SDF-1a overexpression was measured in terms of blood vessel density in the infarct regions after immunostaining for vWF-VIII (Fig. 3) . Blood vessel counts per area were highest in infarct regions with overexpression of SDF-1a.
Effect of hSDF-1a on LV function
Measurement of hemodynamics in vivo showed that LV function was significantly lower in the AdV.SDF-1 group, AdV.LaZ group, and control group than sham operation group. However, improvement of LV function was significantly greater in the AdV.SDF-1 group than in control group. The differences of LVSP (P-0.05), "dpydt and LVEDP max (P-0.05) were statistically significant between the three groups (Fig. 4) .
Discussion
In our and Segret's study, cardiac myocytes and cardiac stemyprogenitor cells have been shown to express CXCR4 w7x. SDF-1a to the cell surface of injured cardiac myocytes could lead to inhibition of myocyte apoptosis as it did to stemyprogenitor cells cultured under ischemic conditions via SDF-1 inducing up-regulation of prosurvival signaling w8x. We found not only that cardiac myocytes had been shown to express SDF-1a receptor CXCR4, and SDF-1a could lead to inhibition of cardiac myocyte apoptosis via SDF-1y CXCR4 axle inducing up-regulation of Akt and Bcl-2. But also, we observed an ;53% decrease in cardiac myocytes apoptosis at the infarct area in those animals that received SDF-1a. These changes could lead to a significant increase in the survival of cardiac myocytes within the infarct zone of those animals that received AdV.SDF-1 injection. Hattori et al. reported that plasma elevation of SDF-1 induced mobilization of hematopoietic stem cells into peripheral blood. We have found that myocardial tissue and plasma SDF-1a concentrations were manifestly increased in AdV.SDF-1 group. Peripheral mononuclear cells (PBMNCs) increased greater than other groups. And there was a prolonged augmented response of PBMNCs count to SDF-1 after MI induction (Supplement 2). Interestingly, much more CD133 EPCs were localized in the area of q overexpressing SDF-1a. These suggested that SDF-1 could induce mobilization of CD133 EPCs and migrate into the q infarct area. On the one hand, these EPCs could proliferate and differentiate into vascular cells w6, 9x. On the other hand, EPCs produce a wide array of arteriogenic cytokines and improve perfusion and remodeling in mouse models of hindlimb ischemia, and these effects appear to be mediated through paracrine mechanisms associated with local release of the arteriogenic cytokines w10x. Furthermore, SDF-1 could promote the expression of angiogenic cytokines such as VEGF, fibroblast growth factor (FGF) and hepatocyte growth factor (HGF), and so on w2, 5x. Also, increased VEGF could involve in or trigger angiogenic progress of stem cells, and even might contribute to postnatal neovascularization by mobilizing bone marrow-derived EPCs w11x. These data suggest that SDF-1 could improve the blood provide of cardiocytes in the infarct area of hearts through the ischemic vasculogenesis and angiogenesis.
In conclusion, SDF-1 could improve cardiac structure and function through the symphysial effect of anti-apoptosis and angiogenesis.
